Evidence map›Paper›PMID 36944188›Full record

ArticleOncotarget2023

Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.

Fang Cheng, Victor Chérouvrier Hansson, Grigorios Georgolopoulos, Katrin Mani

Open access · diamondFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fang ChengDepartment of Experimental Medical Science, Glycobiology Group, Lund University, Biomedical Center A13, Lund, Sweden.
Victor Chérouvrier HanssonDepartment of Experimental Medical Science, Glycobiology Group, Lund University, Biomedical Center A13, Lund, Sweden.
Grigorios GeorgolopoulosGenevia Technologies Oy, Tampere 33100, Finland.
Katrin ManiDepartment of Experimental Medical Science, Glycobiology Group, Lund University, Biomedical Center A13, Lund, Sweden.
Lund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glypicans (GPC1-6) are associated with tumorigenic processes and their involvement in neoplastic behavior has been discussed in different cancer types. Here, a cancer-wide GPC expression study, using clinical cancer patient data in The Cancer Genome Atlas, reveals net upregulation of

Indexed as

AdenocarcinomaCarcinoma, HepatocellularCarcinoma, Transitional CellColonic NeoplasmsGliomaLiver NeoplasmsUrinary Bladder NeoplasmsCell ProliferationGlypicansHumansGlypicansGPC1 protein, humanGPC3 protein, humanGPC5 protein, humanbladder carcinomagliomaGlypican-1hepatocellular carcinomaTCGA

Identifiers

PMID36944188
PMCPMC10030152
OpenAlexW4328129504

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read31
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.